Kris Iyer of Spring Bank to Speak at Nucleic Acid RD Meeting, June 19-20, 2014, San Diego, CA

San Diego, CA (PressExposure) April 01, 2014 -- Kris Iyer, Chief Scientific Officer at Spring Bank Pharmaceuticals, to give a presentation titled "Small Molecule Nucleic Acid Hybrids - A Novel Platform for Small Molecule Drug Discovery" at the Inaugural Nucleic Acid Research and Development Conference, June 29 & 20, 2014 in San Diego, CA.

Radhakrishnan Iyer, (Kris) Ph.D. FRSC., is a widely recognized innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He has been the Principal Investigator for multiple NIH grants for the development of drugs against Hepatitis viruses. Previously, Kris was the co-founder and VP of Discovery of Origenix Technologies, Inc., where he directed a team of 30 scientists in chemistry and biology and was instrumental in advancing several programs from discovery to clinical development. He was an Associate Director of the Discovery program and Technology Development at Hybridon, Inc.

Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, and held Visiting Scientist positions at the University of Texas, M. D. Anderson Cancer Center and at the CBER at FDA/NIH. He received his B.Sc. (Hons) in chemistry, B.Sc. (Tech.), and M.Sc. (Tech.) degrees in Pharmaceuticals and Fine Chemicals from the University of Bombay and Ph.D. in Pharmaceutical Sciences from the University of the Pacific, Stockton, California. Kris carried out postdoctoral work at the Oak Ridge National Laboratory and at the Johns Hopkins University. He has authored over 100 scientific papers, books on organic synthesis and is an inventor of more than 100 filed and issued patents.

This premier conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on the latest discoveries in the Nucleic Acid Field. A balance of both academic and industry experts will facilitate discussion on the following areas:

I. Nucleic Acid as a Drug Target I
II. Emerging Nucelic Acid Technologies
III. Aptamer Design and Application
IV. Nucleic Acid as a Drug Target II

This conference is also part of the 2014 Nucleic Acid Summit which consists of the following co-located conferences:

1. 4th Next-Generation Sequencing Conference
2. Non-Coding RNAs and RNAi Research & Therapeutics
3. Bioinformatics & Pharmacogenomics: Managing and Analyzing Big Data 4. Nucleic Acid Research & Discovery

For more information, please visit

About GTC

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: April 01, 2014 at 10:50 pm
This article has been viewed 35623 time(s).